Market Overview:

Bronchiectasis is a chronic respiratory disease characterized by abnormal irreversible dilatation of bronchi. It occurs due to inflammatory damage to the airways and weakening of the muscles that keep them open. The bronchiectasis drugs market offers a wide range of products including antibiotics, bronchodilators, expectorants and gene therapy which effectively treats associated symptoms such as persistent cough, sputum production and frequent respiratory tract infections.

Market key trends:

Owing to increasing treatment failure rates with antibiotics, there is significant research & development efforts towards gene therapies, monoclonal antibodies and other non-antibiotic novel treatments. For instance, Insmed is developing amikacin liposome inhalation suspension, an antibiotic encapsulated in liposomes for sustained lung delivery and reduced systemic exposure. It received orphan drug designation from the FDA and EMA for management of nontuberculous mycobacterial lung infections in patients with cystic fibrosis and bronchiectasis.

Segment Analysis
The global bronchiectasis drugs market is segmented based on disease condition, drug class, route of administration and distribution channel. Based on disease condition, idiopathic bronchiectasis accounts for the largest market share owing to rising cases of chronic respiratory infections in developing regions. By drug class, antibiotics hold the major share as they are the first line of treatment for tackling infections. Topical formulations dominate the route of administration segment since inhalers and nebulizers provide direct delivery to the lungs. Hospital pharmacies account for the highest share in distribution channels as most bronchiectasis patients require long-term drug therapies.

The global Bronchiectasis Drugs Market Demand is estimated to be valued at US$ 303.8 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Key Takeaways
The global bronchiectasis drugs market is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing prevalence of chronic respiratory diseases.

Regional analysis: North America dominates the global market due to affordable healthcare infrastructure and availability of novel therapies in the region. However, Asia Pacific is expected to grow at the highest CAGR owing to large patient pool and rising healthcare spending in countries like China and India.

Key players analysis: Key players operating in the bronchiectasis drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, Arbor Pharmaceuticals LLC.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it